You are here: Industry Insights > Eisai

News List

FDA Approves DAYVIGO for Insomnia americanpharmaceuticalreview
December 24, 2019
Eisai announced the U.S. Food and Drug Administration (FDA) approved DAYVIGO™ (lemborexant) 5 mg and 10 mg for the treatment of adult patients with insomnia ...
Eisai, Fronteo launch Coroban prediction system for inpatients biospectrumasia
September 27, 2019
Through the launch of the Coroban which supports to establish systems at nursing ward to reduce the tumbling and falling risks of inpatients, Eisai and Fronteo aim to contribute to the realization of well-being of patients and their families.
Eisai to work with Tokio towards prevention of dementia biospectrumasia
September 27, 2019
Eisai and Tokio Marine Nichido will collaborate on initiatives for co-existence and prevention of dementia, including dementia disease awareness initiatives.
Eisai, Meiji receive approval for Parkinson's drug biospectrumasia
September 24, 2019
The most common ADRs (incidence 3% and higher) observed with patients were dyskinesia, falls, and constipation.
Eisai, Meiji receive approval for Parkinson's drug biospectrumasia
September 23, 2019
The most common ADRs (incidence 3% and higher) observed with patients were dyskinesia, falls, and constipation.
Eisai, Mylan to promote anti-cancer drug brands in India biospectrumasia
September 23, 2019
Eisai group positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer.
Eisai, Biogen to Discontinue Elenbecestat Study americanpharmaceuticalreview
September 17, 2019
Eisai and Biogen announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code ...
Eisai, Biogen discontinue clinical studies on AD drug candidate biospectrumasia
September 16, 2019
The accumulation and aggregation of A beta in the brain plays A key role in the pathogenesis of AD. The subtypes of ApoE affect the metabolism, accumulation and deposition of A beta to different degrees.
Eisai launches antimicrobial wet wipes biospectrumasia
September 09, 2019
Etak®, the main ingredient used in the product, is a long-acting antimicrobial agent
Eisai launches antimicrobial wet wipes biospectrumasia
September 08, 2019
Eisai Co., Ltd. has launched Etak® Antimicrobial Wet Wipes (classified as miscellaneous goods) containing long-acting antimicrobial agent Etak® at pharmacies and drugstores countrywide.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page